Charles Lapp: Difference between revisions

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(fix ref, retirement info)
m (Text replacement - " \| ?last(.*)\=(.*)( *)\| ?first(.*)\=(.*)( *)\| ?author" to " |last$1=$2 |first$3$4 |author")
Line 90: Line 90:
==References==
==References==
<references>
<references>
<ref name="Jason, Dec2009">{{Citation
<ref name="Jason, Dec2009">{{Citation |last1  = Jason |first             |authorlink1 = Leonard Jason |last2  = Porter |first           |authorlink2 = Nicole Porter |last3  = Shelleby |first         |authorlink3 = |last4  = Till |first             |authorlink4 = |last5  = Bell |first             |authorlink5 = David Bell |last6  = Lapp |first             |authorlink6 = Charles Lapp |last7  = Rowe |first             |authorlink7 = Kathy Rowe |last8  = De Meirleir |first       |authorlink8 = Kenny De Meirleir
| last1  = Jason            | first1 = Leonard            | authorlink1 = Leonard Jason
| last2  = Porter            | first2 = Nicole            | authorlink2 = Nicole Porter
| last3  = Shelleby          | first3 = E                  | authorlink3 =  
| last4  = Till              | first4 = L                  | authorlink4 =  
| last5  = Bell              | first5 = David S            | authorlink5 = David Bell
| last6  = Lapp              | first6 = Charles W          | authorlink6 = Charles Lapp
| last7  = Rowe             | first7 = Kathy             | authorlink7 = Kathy Rowe
| last8  = De Meirleir      | first8 = Kenny              | authorlink8 = Kenny De Meirleir
| title  = Severe versus Moderate criteria for the new pediatric case definition for ME/CFS
| title  = Severe versus Moderate criteria for the new pediatric case definition for ME/CFS
| journal = Child Psychiatry and Human Development  | volume = 40  | issue = 4  | page = 609-20
| journal = Child Psychiatry and Human Development  | volume = 40  | issue = 4  | page = 609-20
Line 106: Line 98:
}}
}}
</ref>
</ref>
<ref name="JasonL2006paed">{{citation
<ref name="JasonL2006paed">{{citation |last1  = Jason |first           |authorlink1 = Leonard Jason |last2  = Jordan |first           |authorlink2 = Karen Jordan |last3  = Miike |first           |authorlink3 = Teruhisa Miike |last4  = Bell |first             |authorlink4 = David Bell |last5  = Lapp |first             |authorlink5 = Charles Lapp
| last1  = Jason            | first1 = Leonard A          | authorlink1 = Leonard Jason
| last6  = Torres-Harding  | first6 = Susan              | authorlink6 = Susan Torres-Harding |last7  = Rowe |first             |authorlink7 = Kathy Rowe |last8  = Gurwitt |first         |authorlink8 = Alan Gurwitt |last9  = De Meirleir |first     |authorlink9 = Kenny de Meirleir |last10  = Van Hoof |first         10 |authorlink10= Elke Van Hoof
| last2  = Jordan          | first2 = Karen              | authorlink2 = Karen Jordan
| last3  = Miike            | first3 = Teruhisa          | authorlink3 = Teruhisa Miike
| last4  = Bell            | first4 = David S            | authorlink4 = David Bell
| last5  = Lapp            | first5 = Charles            | authorlink5 = Charles Lapp
| last6  = Torres-Harding  | first6 = Susan              | authorlink6 = Susan Torres-Harding
| last7  = Rowe            | first7 = Kathy              | authorlink7 = Kathy Rowe
| last8  = Gurwitt          | first8 = Alan              | authorlink8 = Alan Gurwitt
| last9  = De Meirleir      | first9 = Kenny              | authorlink9 = Kenny de Meirleir
| last10  = Van Hoof        | first10= Elke LS            | authorlink10= Elke Van Hoof
| title  = A Pediatric Case Definition for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome
| title  = A Pediatric Case Definition for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome
| journal = Journal of Chronic Fatigue Syndrome | volume = 13 | issue = 2-3 | page = 1-44
| journal = Journal of Chronic Fatigue Syndrome | volume = 13 | issue = 2-3 | page = 1-44
Line 123: Line 106:
| url    = https://solvecfs.org/wp-content/uploads/2013/06/pediatriccasedefinitionshort.pdf
| url    = https://solvecfs.org/wp-content/uploads/2013/06/pediatriccasedefinitionshort.pdf
}}</ref>
}}</ref>
<ref name="Strayer, 2012">{{Citation
<ref name="Strayer, 2012">{{Citation |last1  = Strayer |first               |authorlink1 = David Strayer |last2  = Carter |first               |authorlink2 = William Carter |last3  = Stouch |first               |authorlink3 = |last4  = Stevens |first               |authorlink4 = Staci Stevens |last5  = Bateman |first               |authorlink5 = Lucinda Bateman |last6  = Cimoch |first               |authorlink6 = |last7  = Lapp |first                 |authorlink7 = Charles Lapp |last8  = Peterson |first             |authorlink8 = Daniel Peterson
| last1  = Strayer              | first1 = DR                  | authorlink1 = David Strayer
| last9  = Chronic Fatigue Syndrome AMP-516 Study Group          | authorlink9 = |last10  = Mitchell |first             10  |authorlink10 = William Mitchell  
| last2  = Carter                | first2 = WA                  | authorlink2 = William Carter
| last3  = Stouch                | first3 = BC                  | authorlink3 =  
| last4  = Stevens              | first4 = SR                  | authorlink4 = Staci Stevens
| last5  = Bateman              | first5 = L                    | authorlink5 = Lucinda Bateman
| last6  = Cimoch                | first6 = PJ                  | authorlink6 =  
| last7  = Lapp                  | first7 = CW                  | authorlink7 = Charles Lapp  
| last8  = Peterson              | first8 = DL                  | authorlink8 = Daniel Peterson
| last9  = Chronic Fatigue Syndrome AMP-516 Study Group          | authorlink9 =  
| last10  = Mitchell            | first10 = WM                  | authorlink10 = William Mitchell  
| title  = A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.
| title  = A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.
| journal = PLoS One    | volume = 7  | issue = 3  | page = e31334
| journal = PLoS One    | volume = 7  | issue = 3  | page = e31334
Line 143: Line 117:
<ref name="Unger, 2017">{{Citation
<ref name="Unger, 2017">{{Citation
| last1  = Unger        | first1 = Elizabeth R. | authorlink1 = Elizabeth Unger
| last1  = Unger        | first1 = Elizabeth R. | authorlink1 = Elizabeth Unger
| last2  = Lin          | first2 = Jin-Mann S.  | authorlink2 = Jin-Mann Sally Lin
| last2  = Lin          | first2 = Jin-Mann S.  | authorlink2 = Jin-Mann Sally Lin |last3  = Tian |first         |authorlink3 =  
| last3  = Tian        | first3 = Hao          | authorlink3 =  
| last4  = Natelson    | first4 = Benjamin H.  | authorlink4 = Benjamin Natelson |last5  = Lange |first       |authorlink5 = Gudrun Lange |last6  = Vu |first           |authorlink6 = |last7  = Blate |first       |authorlink7 = |last8  = Klimas |first       |authorlink8 =  Nancy Klimas   
| last4  = Natelson    | first4 = Benjamin H.  | authorlink4 = Benjamin Natelson  
| last9  = Balbin      | first9 = Elizabeth G. | authorlink9 =   |last10  = Bateman |first     10  |authorlink10 = Lucinda Bateman |last11  = Allen |first       11  |authorlink11 =   
| last5  = Lange        | first5 = Gudrun      | authorlink5 = Gudrun Lange
| last12  = Lapp        | first12 = Charles W.  | authorlink12 =  Charles Lapp |last13  = Springs |first     13  |authorlink13 =   
| last6  = Vu          | first6 = Diana        | authorlink6 =  
| last7  = Blate        | first7 = Michelle    | authorlink7 =  
| last8  = Klimas      | first8 = Nancy G.    | authorlink8 =  Nancy Klimas   
| last9  = Balbin      | first9 = Elizabeth G. | authorlink9 =
| last10  = Bateman     | first10 = Lucinda     | authorlink10 = Lucinda Bateman  
| last11  = Allen      | first11 = Ali        | authorlink11 =   
| last12  = Lapp        | first12 = Charles W.  | authorlink12 =  Charles Lapp  
| last13  = Springs    | first13 = Wendy      | authorlink13 =   
| last14  = Kogelnik    | first14 = Andreas M.  | authorlink14 = Andreas Kogelnik  
| last14  = Kogelnik    | first14 = Andreas M.  | authorlink14 = Andreas Kogelnik  
| last15  = Phan        | first15 = Catrina C.  | authorlink15 =
| last15  = Phan        | first15 = Catrina C.  | authorlink15 =   |last16  = Danver |first     16  |authorlink16 =   
| last16  = Danver      | first16 = Joan        | authorlink16 =   
| last17  = Podell      | first17 = Richard N.  | authorlink17 =  Richard Podell  
| last17  = Podell      | first17 = Richard N.  | authorlink17 =  Richard Podell  
| last18  = Fitzpatrick | first18 = Trisha      | authorlink18 =   
| last18  = Fitzpatrick | first18 = Trisha      | authorlink18 =   
Line 171: Line 136:
}}
}}
</ref>
</ref>
<ref name="Van Hoof, 2007">{{Citation
<ref name="Van Hoof, 2007">{{Citation |last1  = Van Hoof |first       |authorlink1 = Elke Van Hoof |last2  = De Becker |first     |authorlink2 = Pascale De Becker |last3  = Lapp |first           |authorlink3 = Charles Lapp |last4  = Cluydts |first       |authorlink4 = |last5  = De Meirleir |first   |authorlink5 = Kenny de Meirleir
| last1  = Van Hoof      | first1 = E                | authorlink1 = Elke Van Hoof
| last2  = De Becker      | first2 = P                | authorlink2 = Pascale De Becker
| last3  = Lapp          | first3 = C                | authorlink3 = Charles Lapp
| last4  = Cluydts        | first4 = R                | authorlink4 =  
| last5  = De Meirleir    | first5 = K                | authorlink5 = Kenny de Meirleir
| title  = Defining the Occurrence and Influence of Alpha-Delta Sleep in Chronic Fatigue Syndrome
| title  = Defining the Occurrence and Influence of Alpha-Delta Sleep in Chronic Fatigue Syndrome
| journal = The American Journal of the Medical Sciences | volume = 333  | issue = 2  | page = 78-84
| journal = The American Journal of the Medical Sciences | volume = 333  | issue = 2  | page = 78-84
Line 184: Line 144:
}}
}}
</ref>
</ref>
<ref name="Vojdani, 1998">{{Citation
<ref name="Vojdani, 1998">{{Citation |last1  = Vojdani |first     |authorlink1 = |last2  = Choppa |first       |authorlink2 = |last3  = Lapp |first         |authorlink3 = Charles Lapp
| last1  = Vojdani      | first1 = A                  | authorlink1 =  
| last2  = Choppa      | first2 = PC                  | authorlink2 =  
| last3  = Lapp        | first3 = CW                  | authorlink3 = Charles Lapp
| title  = Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome
| title  = Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome
| journal = J Clin Lab Immunol    | volume = 50  | issue = 1  | page = 1-16
| journal = J Clin Lab Immunol    | volume = 50  | issue = 1  | page = 1-16

Revision as of 04:56, May 11, 2022

Source: Hunter-Hopkins Center

Charles W. Lapp, MD, is a retired Internal Medicine physician and the Medical Director Emeritus at Hunter-Hopkins Center in Charlotte, North Carolina, US, which has a practice specializing in ME/CFS, fibromyalgia, and related conditions.[1] Earlier in his career, he practiced family medicine and pediatrics in Raleigh, NC.[2] He became interested in ME/CFS following an outbreak of three small epidemics of a chronic fatiguing illness in the Raleigh area. One of these outbreaks was among all the members of the N.C. Symphony Orchestra.[3]

From 1992 to 1995 Dr. Lapp acted as Medical Director of the Cheney Clinic in Charlotte, in collaboration with Dr. Paul Cheney. In August 1995, Dr. Lapp opened the Hunter-Hopkins Center in Charlotte, North Carolina where he practiced until his retirement in 2018.[2] His center does testing for disability insurance such as the two-day cardiopulmonary exercise test (2-day CPET) and a computer-assisted cognitive function test.

Following Dr. Lapp's retirement in 2018, the Hunter-Hopkins Center director became Dr. Vincent F. Hillman with Dr. Laura Black continuing on staff.[2]

Dr. Lapp serves on the editorial board of the journal, Fatigue: Biomedicine, Health & Behavior, published on behalf of the IACFS/ME.[4]

Awards[edit | edit source]

IOM Committee on Diagnostic Criteria for ME/CFS[edit | edit source]

Dr Lapp was a reviewer for the 2015 report produced by the Institute of Medicine's Committee on Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.[6]

Pediatric Case Definition[edit | edit source]

Clinical Trials[edit | edit source]

The Hunter-Hopkins Center was one of two clinical sites participating in the Hemispherx Biopharma 511/open label Ampligen trials to gain FDA approval, which was ultimately unsuccessful. The Ampligen phase III trial results were published in 2012.[8][9] Ampligen, a brand name for Rintatolimod, is an IV medication, and was given twice weekly at the Hunter-Hopkins infusion room during the trial. The Hunter-Hopkins Center is currently one of four clinics that can administer Ampligen in the US.[9]

Clinic location[edit | edit source]

Dr Lapp retired in 2018, other physicians with expertise in ME/CFS can be contacted at the clinic he founded.

Hunter-Hopkins Center
7421 Carmel Executive Park Dr.
Charlotte, North Carolina 28226
Telephone: (704) 543-9692
Email: drlapp@drlapp.net

Notable studies[edit | edit source]

Talks and interviews[edit | edit source]

Grand Rounds Video
Grand Rounds Presentation Slide Deck

HHS/CFSAC Testimony[edit | edit source]

Open Letter to The Lancet[edit | edit source]

Three open letters to the editor of The Lancet urged the editor to commission a fully independent review of the PACE trial, which the journal had published in 2011. In 2016, Dr. Lapp, along with 42 colleagues in the ME/CFS field, signed the second letter.[22] In 2018, Dr. Lapp, with more than 100 colleagues in the ME/CFS field, signed the third letter.[23]

Online presence[edit | edit source]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. "Curriculum Vitae – Charles W. Lapp, MD". Hunter-Hopkins Center. Retrieved October 26, 2020.
  2. 2.0 2.1 2.2 Lapp, Charles (February 12, 2018). "Dr. Lapp Retires and Dr. Vincent Hillman Takes the Helm". Hunter-Hopkins Center. Retrieved December 23, 2018.
  3. Garloch, Karen (2009). "Cause of illness remains unknown". NewsOK.
  4. "Fatigue: Biomedicine, Health & Behavior". www.tandfonline.com. Retrieved November 1, 2019.
  5. "IACFS/ME Awardees". IACFS/ME. Retrieved April 23, 2020.
  6. Institute of Medicine. "ME/CFS Presentation" (PDF). National Academies Press. Retrieved December 23, 2018.
  7. 1first 2 first 1 first 3 first 2, "A Pediatric Case Definition for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome" 
  8. 8.0 8.1 1first 2 first 1 first 3 first 2, "A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome." 
  9. 9.0 9.1 Hunter-Hopkins Center. "Ampligen | Research | Hunter-Hopkins Center, P.A." Retrieved December 23, 2018.
  10. Charles W. Lapp. (1997). Management of Chronic Fatigue Syndrome in Children: A Practicing Clinician's Approach. Journal of Chronic Fatigue Syndrome, Vol. 3, Iss. 2, pp 59-76. http://dx.doi.org/10.1300/J092v03n02_07
  11. 1first 2 first 1 first 3 first 2, "Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome" 
  12. Aristo Vojdani & Charles W. Lapp. (1999). The Relationship Between Chronic Fatigue Syndrome and Chemical Exposure. Journal of Chronic Fatigue Syndrome, Vol. 5, Iss. 3-4, pp. 207-221. http://dx.doi.org/10.1300/J092v05n03_18
  13. Charles W. Lapp. (2006). Recognizing Pediatric CFS in the Primary Care Practice: A Practicing Clinician's Approach. Journal of Chronic Fatigue Syndrome, Vol. 13, Iss. 2-3, pp. 89-96. http://dx.doi.org/10.1300/J092v13n02_06
  14. 1first 2 first 1 first 3 first 2, "Defining the Occurrence and Influence of Alpha-Delta Sleep in Chronic Fatigue Syndrome" 
  15. 1first 2 first 1 first 3 first 2, "Severe versus Moderate criteria for the new pediatric case definition for ME/CFS" 
  16. Irlbeck, David M.; Vernon, Suzanne D.; McCleary, K. Kimberly; Bateman, Lucinda; Klimas, Nancy G.; Lapp, Charles W.; Peterson, Daniel L.; Brown, James R.; Remlinger, Katja S.; Wilfret, David A.; Gerondelis, Peter (2014). "No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment and use of the SolveCFS BioBank". BMC Research Notes. 7: 461. doi:10.1186/1756-0500-7-461.
  17. Unger, ER; Lin, JS; Brimmer, DJ; Lapp, CW; Komaroff, AL; Nath, A; Laird, S; Iskander, J (2016). "CDC Grand Rounds: Chronic Fatigue Syndrome — Advancing Research and Clinical Education". Morbidity and Mortality Weekly Report. 65 (5051): 1434–1438. doi:10.15585/mmwr.mm655051a4. -
  18. 3first 5 first 3 first 6 first 5, "Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study." 
  19. Lapp, Charles W. (January 2019). "Initiating Care Of A Patient With Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS)". Frontiers in Pediatrics. doi:10.3389/fped.2018.00415.
  20. Proskauer, Charmian; Rowe, Peter C.; Lapp, Charles W.; DeMaria, Alfred Jr; Bateman, Lucinda; Attewell, John R.; Proskauer, Daniel; Kiernicki, David J.; Adebayo, Seyi (2019). "Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning". Frontiers in Pediatrics. 6. doi:10.3389/fped.2018.00412. ISSN 2296-2360. PMID 30671425.
  21. Campbell, Bruce. "Dr Lapp's Recommendations on Supplements | ME/CFS & Fibromyalgia Self-Help". www.cfidsselfhelp.org. Retrieved December 23, 2018.
  22. "Open Letter Lancet Again".
  23. "An Open Letter to The Lancet, Two Years On".
  24. Johnson, Cort (March 28, 2018). "An ME/CFS and FM Pioneer Says Good-bye: The Charles Lapp Interview". Health Rising. Retrieved December 23, 2018.